The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.
 
Primo Lara
Consulting or Advisory Role - CellMax Life; Janssen; Merck; Pfizer
Research Funding - Aragon Pharmaceuticals (Inst); Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); TRACON Pharma (Inst)
 
Edward Mayerson
No Relationships to Disclose
 
Erik Gertz
No Relationships to Disclose
 
Catherine Tangen
No Relationships to Disclose
 
Amir Goldkorn
Consulting or Advisory Role - Acadia Wood
Research Funding - Angle; Clearbridge Biomedics; Cynvenio Biosystems; Menarini Silicon Biosystems; RareCyte; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - I am listed as a co-inventor on a patent held jointly by USC and Caltech for a microfilter we developed for capturing live circulating tumor cells from blood.
 
Marta Van Loan
No Relationships to Disclose
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; Astellas Pharma; Genentech; MLI PeerView; PER; PER; Phillips Gilmore Oncology; projects in Knowledge; Research to Practice; Research to Practice; Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Genentech; Genentech/Roche; Pfizer
 
Shilpa Gupta
Stock and Other Ownership Interests - Nektar
Honoraria - AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology
Research Funding - Astellas Medivation (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Merck; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Clovis oncology; Dendreon; Janssen Oncology; Seagen
Speakers' Bureau - Merck Sharp & Dohme; Sanofi
Research Funding - AstraZeneca/MedImmune (Inst)
 
Przemyslaw Twardowski
Honoraria - Astellas Medivation; Bayer; Genentech/Roche; Janssen; Sanofi/Aventis
Consulting or Advisory Role - Janssen; Sanofi/Aventis
Speakers' Bureau - Astellas Pharma; Bayer; Genentech/Roche; Janssen; Sanofi
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Mundipharma; Novartis; Pfizer; Pharmacyclics; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Seagen; US Biotest
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Exelixis; Merck; Roche
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Novartis; Pfizer; UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Caris Life Sciences; Clovis Oncology; Corvus Pharmaceuticals; Eisai; Genentech/Roche; Janssen Oncology; Merck; Modra Pharmaceuticals; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Genentech/Roche; Sanofi
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; Sanofi/Aventis; US Oncology
 
Ian Murchie Thompson
Consulting or Advisory Role - Magforce; Profound Medical
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Foundation One Inc; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)